Default Theme
AIIMS NEW
-
अखिल भारतीय आयुर्विज्ञान संस्थान, नई दिल्ली
All India Institute Of Medical Sciences, New Delhi

DR. SACHIN KUMAR

 

SACHIN KUMAR  

Date of Birth               2nd May, 1982

Address                       Room No. 401, 4th Floor, Dept. of Medical Oncology, Dr. BRA Institute Rotary Cancer Hospital, AIIMS, New Delhi-110029

Tel.  No.                       +91-11-29575401 (Office); +91-8076277279 (Mobile)

E-mail                            This email address is being protected from spambots. You need JavaScript enabled to view it. ; This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Educational Qualifications  

PhD (Cancer Research) from Dept. of Medicine, All India Institute of Medical Sciences, New Delhi, India (Year 2005-2010)  

Title of PhD thesis: Clinical Implications of Circulating DNA and Protein Markers in Lung Cancer  

MSc (Biotechnology) from Maharshi Dayanand University, Rohtak, Haryana, India (Year 2002-2004) 

BSc (Zoology, Botany, Chemistry) from Vaish PG College, Bhiwani, Haryana, India (Year 1999-2002)

 

Academic/Research Experience  

Scientist II                   Dept. of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences,                                      Ansari Nagar, New Delhi, India (16/09/2016 till date)  

Assistant                     Amity Institute of Biotechnology & Amity Institute of Molecular Medicine & Stem Cell Professor                   Research, Amity University Uttar Pradesh (Noida), India (12/03/2012 till 15/09/2016)  

Postdoctoral               Dept. of Human & Molecular Genetics, Virginia Commonwealth University, Richmond, Fellow                        Virginia, USA (19/10/2010 till 28/01/2012)  

Sr. Research               National Institute of Cancer Prevention & Research (Formerly ICPO), Noida, Uttar Fellow                            Pradesh, India (05/05/2010 till 11/10/2010)

    

Research Projects   

Ongoing

  1. Elucidation of the role of long non-coding RNA-Ginir as a biomarker in lung tumorigenesis. Funding Agency: DBT; Duration: 03 years; Funds: 89 lakhs (In collaboration with NCCS, Pune; Role: Co-PI)
  2. Evaluation of regulation of programmed death-ligand 1 (PD-L1) expression by microRNA in lung cancer. Funding Agency: ICMR; Duration: 8/2019-8/2022; Funds: 47.64 lakhs (Role: PI)
  3. Liquid Biopsy: An exploratory study on exosomes based diagnostics for lung cancer. Funding Agency: AIIMS-IIT-Delhi; Duration: 11/2018-11/2020; Funds: 20 lakhs (Role: Co-investigator)
  4. Clinical significance of cell-free DNA in intraoperative pleural lavage fluid and plasma in patients undergoing pulmonary metastasectomy. Funding Agency: AIIMS; Duration: 09/2018-09/2020; Funds: 10 lakhs (Role: Co-investigator)

Completed  

  1. Identification of a dysregulated circulating miRNA signature in non-small cell lung cancer. Funding Agency: SERB-DST; Duration: 9/2014-12/2017; Funds: 23 lakhs (Role: PI)
  2. Investigating the efficacy of microRNAs as molecular marker in cytogenetically normal pediatric acute myeloid leukemia. Funding Agency: DBT; Duration: 02/2015-08/2018; Funds: 65.51 lakhs (Role: Project coordinator and PI)
  3. Elucidating the mechanism of regulation of PD-L1 expression in lung cancer – role of epigenetics and copy number alterations. Funding Agency: AIIMS; Duration: 09/2017-09/2019; Funds: 10 lakhs (Role: PI)
  4. The clinical significance of HOTAIR and HOTAIRM1 long non-coding RNAs in pediatric acute myeloid leukemia. Funding Agency: AIIMS; Duration: 08/2017-08/2019; Funds: 9 lakhs (Role: Co-investigator)

 

Publications[Total Citations: 962; h-index: 13 (Stats from Google Scholar)]  

  1. Kumar S*, Pandey M, Sharawat SK. Biological functions of long noncoding RNAs and circular RNAs in small-cell lung cancer. Epigenomics 2020 (Accepted for Publication). Impact Factor: 4.112.
  2. Kumar S*, Sharawat SK, Ali A, Gaur V, Malik PS, Pandey M, Kumar S, Mohan A, Guleria R. Differential expression of circulating serum miR-1249-3p, miR-3195 and miR-3692-3p in non-small cell lung cancer. Human Cell 2020; 33:839-849. doi: 10.1007/s13577-020-00351-9. Impact Factor: 3.463.
  3. Kumar S*, Sharawat SK, Ali A, Gaur V, Malik PS, Kumar S, Mohan A, Guleria R. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Curr Probl Cancer 2020; 44(4): 100540. Citation: 5; Impact Factor: 3.264. https://doi.org/10.1016/j.currproblcancer.2020.100540
  4. Gaur V, Chaudhary S, Tyagi A, Agarwal S, Sharawat SK, Sarkar S, Singh H, Bakhshi S, Sharma P, Kumar S*. Dysregulation of miRNA expression and their prognostic significance in pediatric cytogenetically normal acute myeloid leukemia. British J of Hematology 2020; 188(6): e90-e94.  Impact Factor: 5.518. https://doi.org/10.1111/bjh.16375 
  5. Bhat AA, Younes SM, Raza SS, Zarif L, Nisar S, Ahmed I, Mir R, Kumar S, Sharawat SK, Hashem S, Elfaki I, Kulinski M, KuttiKrishnan, S, Prabhu KS, Khan AQ, Yadav SK, El-Rifai W, Zargar MA, Zayed H, Haris M, Uddin S. Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. Mol Cancer 2020; 19(1): 57. Citations: 5; Impact Factor: 15.302. https://doi.org/10.1186/s12943-020-01175-9
  6. Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget 2019; 10(42): 4262-4275. Citations: 5; Impact Factor: 5.168. https://doi.org/10.18632/oncotarget.27008
  7. Khurana S, Kumar S, Guleria R, Choudhury S, Gaur V, Saha B, Bose S. Molecular signatures of microRNA in obesity associated obstructive sleep apnea in middle-aged adults. International Journal of Medical Research and Health Sciences 2019; 8(11): 57-66. Impact Factor: 0.52
  8. Khurana S, Sharda S, Saha B, Kumar S, Guleria R, Bose S. Canvassing the etiology, prognosis and molecular signatures of obstructive sleep apnea. Biomarkers 2019; 24:1-16. Citations: 3; Impact Factor: 2.07. https://doi.org/10.1080/1354750X.2018.1514655
  9. Kumar S*, Sharawat SK. Epigenetic regulators of programmed death-ligand 1 expression in human cancers. Translational Research 2018; 202:129-145. Citations: 13; Impact Factor: 5.411. https://doi.org/10.1016/j.trsl.2018.05.011
  10. Kumar S*, Gaur V, Khurana S, Bose S, Kiran M, Sharawat SK. Proteomics – An update on recent tools and techniques. EC Proteomics and Bioinformatics 2018 February 8; 2(2):57-73.
  11. Ali A, Kumar S, Kakaria VK, Mohan A, Luthra K, Upadhyay AD, Guleria R. Detection of promoter DNA methylation of APC, DAPK, and GSTP1 genes in tissue biopsy and matched serum of advanced stage lung cancer patients. Cancer Invest 2017; 35(6):423-430.Citations: 4; Impact Factor: 2.398. https://doi.org/10.1080/07357907.2017.1309547
  12. Kumar S*, Bakhshi S. The diagnostic and prognostic role of microRNAs in pediatric acute myeloid leukemia – a review. Indian Journal of Medical Research 2016; 144(6):807-814.Citations: 2; Impact Factor: 1.503. doi: 10.4103/ijmr.IJMR_220_15
  13. Singh DK, Bose S, Kumar S*. Role of microRNA in regulating cell signaling pathways, cell cycle, and apoptosis in non-small cell lung cancer. Curr Mol Med 2016; 16(5): 474-486. Citations: 11; Impact Factor: 1.6. DOI: 10.2174/1566524016666160429120702
  14. Singh DK, Bose S, Kumar S*. Regulation of expression of microRNAs by DNA methylation in lung cancer. Biomarkers 2016; 21(7):589-599. Citations: 10; Impact Factor: 2.07. https://doi.org/10.3109/1354750X.2016.1171906
  15. Bose S, Ganguly S, Kumar S, Bookckfer FR. A Pit-1 binding site adjacent to E-Box 133 in the rat PRL promoter is necessary for pulsatile gene expression activity. Neurochem Res 2016; 41(6):1390-1400.Citations: 2; Impact Factor: 3.038. https://doi.org/10.1007/s11064-016-1843-y
  16. Tilak AR, Kumar S, Pant MC, Mathur N, Kumar A. Polymorphism Arg72Pro of p53 confers susceptibility to squamous cell carcinoma of lungs in a north Indian population. DNA Cell Biol 2013; 32(2):66-72.Citations: 7; Impact Factor: 3.191. https://doi.org/10.1089/dna.2012.1792
  17. Quinn BA, Dash R, Azab B, Sarkar, S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20(10):1397-1411. Citations: 199; Impact Factor: 5.081. https://doi.org/10.1517/13543784.2011.609167
  18. Tilak AR, Kumar S, Jain M, Pant MC, Das BC, Guleria R, Mittal B, Mathur R, Kumar A. Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility. Cancer Invest 2011; 29(6):411-418. Citations: 24; Impact Factor: 2.398. https://doi.org/10.3109/07357907.2011.587070
  19. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer. Cancer Invest 2011; 29(3):202-207. Citations: 27; Impact Factor: 2.398. https://doi.org/10.3109/07357907.2010.543208
  20. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of circulating plasmaDNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 2010; 70(2):211-217. Citations: 50; Impact Factor: 4.702. https://doi.org/10.1016/j.lungcan.2010.01.021
  21. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma DNA level inpredicting therapeutic efficacy in advanced non-small cell lung cancer. Eur Respir J 2010; 36(4):885-892. Citations: 41; Impact Factor: 12.339. https://doi.org/10.1183/09031936.00187909
  22. Kumar S, Guleria R, Singh V, Mohan A, Bharti AC, Das BC. Lack of utility of plasmaTNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer. Cytokine 2010; 51(3):245-248. Citations: 3; Impact Factor: 2.952. https://doi.org/10.1016/j.cyto.2010.05.007
  23. Kumar S, Guleria R, Mohan A, Singh V, Ali A, Bharti AC, Das BC. Utility of plasmatumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma. Biomarkers 2010; 15 (5):446-453. Citations: 10; Impact Factor: 2.07. https://doi.org/10.3109/1354750X.2010.485699
  24. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma nucleosome levelsmight predict response to therapy in patients with advanced non-small cell lung cancer. Clin Lung Cancer 2010; 11(1):36-44.Citations: 25; Impact Factor: 3.55.https://doi.org/10.3816/CLC.2010.n.006
  25. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of plasma vascularendothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer. BMC Cancer 2009; 9(1):421.Citations: 18; Impact Factor: 3.15. https://doi.org/10.1186/1471-2407-9-421
  26. Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R. A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis. Asian Pac J Cancer Prev 2009; 10(3):335-338. Citations: 59; Impact Factor: 1.23; PMID: 19640168
  27. Kumar S, Mohan A, Guleria R. Prognostic implications of circulating anti-p53 antibodies inlung cancer-a review. Eur J Cancer Care 2009; 18(3):248-254. Citations: 35; Impact Factor: 2.161. https://doi.org/10.1111/j.1365-2354.2008.01019.x
  28. Mohan A, Singh P, Kumar S, Mohan C, Pathak AK, Pandey RM, Guleria R. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2008; 9(4): 557-562. Citations: 57; Impact Factor: 1.23; PMID: 19256738
  29. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006; 52(10):1833-1842. Citations: 234; Impact Factor: 7.292. https://doi.org/10.1373/clinchem.2005.062893/
  30. Kumar S, Mohan A, Guleria R. Biomarkers in cancer screening, research and detection:present and future: a review. Biomarkers 2006; 11(5):385-405. Citations: 115; Impact Factor: 2.07. https://doi.org/10.1080/13547500600775011
  31. Kumar S, Singh V, Chandra S, Agarwal D, Mohan A, Guleria R. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer 2009; 65(2):254. Impact Factor: 4.702; PMID: 19398240 (Letter to Editor).

 (* As corresponding author)  

Abstracts  

  1. Kumar S, Sharawat SK, Ali A, Malik PS, Mohan A, Guleria R. Diagnostic and prognostic utility of differentially expressed circulating microRNAs in Indian NSCLC patients. J Thor Oncol 2019; 14 (10): S960-S961.
  2. Malik PS, Yadav A, Jain D, Pathy S, Mohan A, Khurana S, Kumar S. Pemetrexed-carboplatin versus paclitaxel (weekly)-carboplatin as first line chemotherapy in advanced non-squamous NSCLC. J Thor Oncol 2019; 14 (10): S354-355.
  3. Verma S, Malik PS, Yadav A, Jain D, Khurana S, Kumar S. Thymidylate synthase and folate receptor alpha expression as potential biomarkers for efficacy of pemetrexed in NSCLC. J Thor Oncol 2019; 14 (10): S939.
  4. Gaur V, Chaudhary S, Tyagi A, Bakhshi S, Sharma P, Kumar S. Differential expression of various miRNAs in pediatric cytogenetically normal acute myeloid leukemia (CN-AML). Annals of Oncology 2019; 30 (Supplement 5): v50-v51.
  5. Gaur V, Chaudhary S, Tyagi A, Bakhshi S, Sharma P, Kumar S. Dysregulated microRNA expression in pediatric cytogenetically normal acute myeloid leukemia patients. Proceedings of the American Association for Cancer Research 2019; 60:460-461.
  6. Kumar S, Ali A, Guleria R. Identification of differentially expressed circulating miRNAs in the serum of NSCLC patients using next generation sequencing. J Thor Oncol 2017; 12(S1): S411.
  7. Ali A, Kumar S, Kakaria V, Mohan A, Luthra K, Upadhyay A, Guleria R. Detection of promoter DNA methylation of APC, DAPK, and GSTP1 genes in tissue biopsy and matched serum of advanced stage lung cancer patients. J Thor Oncol 2017; 12(S1): S410.
  8. Guleria R, Mohan A, Kumar S, Ali A, Kumar A. Survival outcomes in advance non-small cell lung cancer – a developing country scenario. Eur Respir J 2011; 38: Suppl. 55, 815S.
  9. Das BC, Bharti AC, Mohan A, Guleria R, Kumar R, Kumar S. Vascular endothelial growth factor (VEGF) as a marker of response to therapy in lung cancer. Indian J Cancer 2008; 45 (suppl): S22.
  10. Mohan A, Guleria R, Kumar S, Mohan C, Pathak AK, Pandey RM. Impact of symptoms, respiratory status, nutritional profile and quality of life in patients with advanced non small cell lung cancer. Chest 2007 (Suppl): 132 (4); 589S.

Awards / Honors  

  • Young Investigator Award for best oral presentation in NALCCON 2019: 10th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized at KGMU, Lucknow on 14-15 Dec. 2019.
  • 1st Prize in oral paper presentation in NALCCON 2018: 9th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized at AIIMS Patna on 6-7th October, 2018.
  • 2nd Prize for poster presentation in International Symposium on "Frontiers in Cancer Research: Prevention to Therapeutics" held during November 15-16, 2013 at Amity University Uttar Pradesh.
  • Elected Finance Secretary of Society of Young Scientists (SYS), AIIMS (2009-10).
  • 3rd Prize in the International Competition on Article Writing: 2009 (Proteomics) organized by Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India.
  • The Best Poster Award in RGCON 2009: 8th International Conference on Lung and Esophageal Cancers held at Rajiv Gandhi Cancer Institute & Research Centre, Delhi.
  • Special Appreciation Award in IACR (Indian Association for Cancer Research) essay competition 2008 on “Bioinformatics in Cancer Drug Design”.
  • Citation Award in IACR (Indian Association for Cancer Research) essay competition 2006 for the best essay on “Cancer Stem Cells”.
  • Qualified Junior Research Fellowship (JRF-NET) in life science, conducted by Council of Scientific and Industrial Research (CSIR) in June 2004.
  • Qualified Junior Research Fellowship (JRF-NET) in life science, conducted by Council of Scientific and Industrial Research (CSIR) in December 2003.
  • Qualified ICMR JRF examination conducted on July 11, 2004 as Junior Research Fellow in ICMR Funded Research Projects/Scheme.
  • Merit certificate for standing second in the college in the university examination in B.Sc-3rd year from Vaish P.G. College, Bhiwani in April 2002.
  • Merit certificate for standing first in the college in the university examination in B.Sc-2nd year from Vaish P.G. College, Bhiwani in April 2001.
  • Distinction in matriculation examination conducted by Board of School Education Haryana in 1997.

Editorial Board Member  

  1. Associate Editor (Cancer Section) of BMC Pulmonary Medicine (Springer Nature)

Journals/Grant Reviewer (Ad-hoc)  

Scientific Reports, Molecular Oncology, Carcinogenesis, American Journal of Clinical Oncology, Current Problems in Cancer, BMC Cancer, BMC Pulmonary Medicine, European Journal of Cancer Care, Cancer Biomarkers, Cancer Biotherapy and Radiopharmaceuticals, OncoTargets and Therapy, Personalized Medicine, Genetic Testing and Molecular Biomarkers, Human Cell, Lung Cancer: Targets & Therapy, Cancer Management & Research, Cell Biology International, Medical Science Monitor, Technology in Cancer Research & Treatment, Endocrine Connections, Translational Medicine Communications, Pathology - Research and Practice, 3Biotech, Computational Biology and Chemistry, Sultan Qaboos University Medical Journal  

Reviewed SERB-DST extramural grant for funding; Reviewed ICMR fellowship reports

Membership

  • Active Member (#429524) of International Association for the Study of Lung Cancer (IASLC)
  • Life Member of Indian Society for Study of Lung Cancer (ISSLC)
  • Associate Member of Cancer Epigenetics Society

Teaching Experience

Four and half years of teaching experience in subjects like Animal Biotechnology, Cancer Biology, Molecular Cell Biology, Recombinant DNA Technology and Gene Therapy (at UG/PG/PhD level)  

Oral Talks / Invited Lectures

  1. Oral talk on “Evaluation of deregulated circulating microRNA expression in advanced stage NSCLC patients” during NALCCON 2019 – 10th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized at KGMU, Lucknow from 14-15 December, 2019.
  2. Invited oral talk on “Prognostic significance of dysregulated microRNA expression in pediatric cytogenetically normal acute myeloid leukemia” at IACR 2019: Integrating Cancer Research into Comprehensive Disease Management: Recent Breakthroughs organized by PGIMER, Chandigarh from 1-3 March, 2019.
  3. Oral talk on “Evaluation of the expression and regulation of programmed death ligand-1 (PD-L1) in lung cancer” at NALCCON 2018 - 9th Annual Conference of Indian Society for Study of Lung Cancer (ISSLC) organized at AIIMS Patna on 6-7th October, 2018.
  4. Expert talk on “Detection of epigenetic alterations in circulating DNA/RNA as biomarkers in lung cancer” at World Cancer Congress held at Science City, Kolkata, WB, India from 20-22 Sept, 2017.

Posters Presented In Conference/Symposium  

  1. Kumar S, Sharawat SK, Ali A, Malik PS, Mohan A, Guleria R. Diagnostic and prognostic utility of differentially expressed circulating microRNAs in Indian NSCLC patients (EP1.03-20). E-poster presented in IASLC 2019 World Conference on Lung Cancer held at Barcelona, Spain from 7-10 Sept, 2019.
  2. Gaur V, Bakhshi S, Sharma P, Kumar S. Dysregulated microRNA expression in the bone marrow of pediatric cytogenetically normal acute myeloid leukemia patients. Poster presented in 38th IACR Convention 2019 organized at PGIMER and Hotel Mountview, Chandigarh from 1-3 March, 2019.
  3. Gaur V, Bakhshi S, Sharma P, Kumar S. Small RNA sequencing reveals deregulated microRNA expression in the bone marrow of pediatric cytogenetically normal acute myeloid leukemia patients. Poster presented in 37th IACR Convention 2018 organized at Bose Institute, Salt Lake, Kolkata from Feb 23-25, 2018.
  4. Kumar S, Fisher PB. Using a cancer terminator virus (Ad.5/3-CTV) to improve the efficiency of hepatocellular cancer gene therapy. International Symposium on "Frontiers in Cancer Research: Prevention to Therapeutics" held during November 15-16, 2013 at Amity University Uttar Pradesh.
  5. Kumar S, Guleria R, Mohan A, Bharti AC, Das BC. Plasmanucleosome levels may predict therapeutic efficacy in patients with advanced non-small cell lung cancer. 3rd International Symposium on Translational Cancer Research. Bhubaneswar, Orissa, India, December 2009.
  6. Kumar S, Guleria R, Singh VK, Chandra S, Bharti AC, Das BC. Vascular endothelial growth factor (VEGF) in correlation with various clinico-pathological parameters in lung cancer. RGCON 2009: 8th International Conference on Lung and Esophageal Cancers. Rajiv Gandhi Cancer Institute & Research Centre, Delhi, March 2009.
  7. Kumar S, Das BC, Bharti AC, Mohan A, Guleria R, Kumar R. Vascular endothelial growth factor (VEGF) as a marker of response to therapy in lung cancer. 3rd Asia Pacific Lung Cancer Conference (APLCC), Hyderabad, India (2008).

Symposium Organized  

  1. Organized (as a Finance Secretary) one day national symposium on “Translational Research in Health Sciences” at AIIMS, NewDelhi, India on 24th November 2009.

Profile links

1.    ORCID: https://orcid.org/0000-0002-2594-6770  

2.    Google Scholar: https://scholar.google.co.in/citations?user=MdG99mEAAAAJ&hl=en

3.    Webpage: https://sachinkumarlab.webs.com/ 

 

 

 

Contact Us

All India Institute of Medical Sciences

Ansari Nagar, New Delhi - 110029

Board Number : +91-11-26588500 / 26588700

Fax : +91-11-26588663 / 26588641

AIIMS Exam Section Helpline numbers ( Click Here)

Important E-mail Addresses at AIIMS

Zo2 Framework Settings

Select one of sample color schemes

Google Font

Menu Font
Body Font
Heading Font

Body

Background Color
Text Color
Link Color
Background Image

Header Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Menu Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Main Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Inset Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Bottom Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image
Background Color
Modules Title
Text Color
Link Color
Background Image
 
Top of Page